AU2012379655B2 - Method for inducing UDP-glucuronosyltransferase activity using pterostilbene - Google Patents

Method for inducing UDP-glucuronosyltransferase activity using pterostilbene Download PDF

Info

Publication number
AU2012379655B2
AU2012379655B2 AU2012379655A AU2012379655A AU2012379655B2 AU 2012379655 B2 AU2012379655 B2 AU 2012379655B2 AU 2012379655 A AU2012379655 A AU 2012379655A AU 2012379655 A AU2012379655 A AU 2012379655A AU 2012379655 B2 AU2012379655 B2 AU 2012379655B2
Authority
AU
Australia
Prior art keywords
pterostilbene
ugt
effective amount
therapeutically effective
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2012379655A
Other languages
English (en)
Other versions
AU2012379655A1 (en
Inventor
Jeremy BARTOS
Ryan DELLINGER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chromadex Inc
University of California, San Diego
Original Assignee
Chromadex Inc
University of California Berkeley
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chromadex Inc, University of California Berkeley, University of California, San Diego filed Critical Chromadex Inc
Publication of AU2012379655A1 publication Critical patent/AU2012379655A1/en
Application granted granted Critical
Publication of AU2012379655B2 publication Critical patent/AU2012379655B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2012379655A 2012-05-08 2012-11-14 Method for inducing UDP-glucuronosyltransferase activity using pterostilbene Expired - Fee Related AU2012379655B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/466,827 2012-05-08
US13/466,827 US8841350B2 (en) 2011-05-11 2012-05-08 Method for inducing UDP-glucuronosyltransferase activity using pterostilbene
PCT/US2012/064993 WO2013169291A2 (en) 2012-05-08 2012-11-14 Method for inducing udp-glucuronosyltransferase activity using pterostilbene

Publications (2)

Publication Number Publication Date
AU2012379655A1 AU2012379655A1 (en) 2014-11-20
AU2012379655B2 true AU2012379655B2 (en) 2018-01-18

Family

ID=47142275

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012379655A Expired - Fee Related AU2012379655B2 (en) 2012-05-08 2012-11-14 Method for inducing UDP-glucuronosyltransferase activity using pterostilbene

Country Status (12)

Country Link
US (2) US8841350B2 (enExample)
EP (1) EP2846785A4 (enExample)
JP (1) JP2015523963A (enExample)
KR (1) KR20150027081A (enExample)
CN (1) CN104768543A (enExample)
AU (1) AU2012379655B2 (enExample)
BR (1) BR112014027646A2 (enExample)
CA (1) CA2872623A1 (enExample)
IN (1) IN2014DN09990A (enExample)
MX (1) MX2014013503A (enExample)
WO (1) WO2013169291A2 (enExample)
ZA (1) ZA201408893B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017004304B1 (pt) * 2014-09-04 2020-12-08 The Regents Of The University Of California uso de pteroestilbeno para prepação de composições tópicas no tratamento de perda de função de barreira na pele induzidas por uv
WO2016037007A1 (en) * 2014-09-04 2016-03-10 The Regents Of The University Of California Topical pterostilbene compositions for use in treating uv-induced skin damage and hyperplasia
CN107849083A (zh) 2015-06-10 2018-03-27 益力舒健康公司 用于治疗皮肤病症的烟酰胺核苷和紫檀芪组合物和方法
US12134956B2 (en) 2022-10-11 2024-11-05 Halliburton Energy Services, Inc. Liner hanger system
US12398624B2 (en) 2023-07-11 2025-08-26 Halliburton Energy Services, Inc. Self-energizing seal for expandable liner hanger
US12509957B1 (en) 2024-09-16 2025-12-30 Halliburton Energy Services, Inc. Partially bonded seals for well systems

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090175803A1 (en) * 2008-01-08 2009-07-09 David Rubin Method and compositions for administering resveratrol and pterostilbene
WO2011051483A1 (en) * 2009-10-30 2011-05-05 Green Molecular, S.L Pterostilbene (pter) for use in the prevention and/or treatment of skin diseases, damages or injures
US20110136751A1 (en) * 2009-10-06 2011-06-09 Green Molecular Use of Polyphenols in the Treatment of Cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6623724B2 (en) * 1996-09-18 2003-09-23 Applied Genetics Incorporated Dermatics Dermatological compositions and methods
US6414037B1 (en) * 1998-01-09 2002-07-02 Pharmascience Pharmaceutical formulations of resveratrol and methods of use thereof
DE10161253A1 (de) 2001-12-13 2003-06-26 Dragoco Gerberding Co Ag Verwendung von Dihydropinosylvin und dessen Derivaten als Inhibitoren
FR2869229B1 (fr) 2004-04-26 2006-08-25 Sederma Soc Par Actions Simpli Utilisation d'un inducteur des ugt par voie topique
ES2246165B1 (es) 2004-07-20 2006-12-01 Universitat De Valencia Uso combinado del pteroestilbeno y la quercetina para la fabricacion de medicamentos utiles en el tratamiento del cancer.
US8426369B2 (en) 2006-12-07 2013-04-23 Rutgers, The State University Of New Jersey Prevention and treatment of colon cancer
US8509879B2 (en) 2007-11-06 2013-08-13 The Regents Of The University Of California Apparatus and method for widefield functional imaging (WiFI) using integrated structured illumination and laser speckle imaging
US20090324740A1 (en) 2008-06-13 2009-12-31 Albritton Iv Ford D Novel nasal spray
US20100240767A1 (en) 2009-03-23 2010-09-23 Muhammed Majeed Melanogenesis inhibitiuon by 3,5-dimethoxy-4'-hydroxystilbenes and cosmeceutical compositions thereof
EP2445488B1 (en) 2009-06-22 2020-03-18 Indus Biotech Private Limited Process for obtaining purified pterostilbene and methods of use thereof
US8513236B2 (en) * 2010-02-03 2013-08-20 Laurus Labs Private Limited Pterostilbene cocrystals
US8883218B2 (en) * 2010-03-26 2014-11-11 The Board Of Trustees Of The University Of Arkansas Anti-cancer nanoparticle compositions and methods of use
CA2826034A1 (en) 2011-01-28 2012-08-02 University Of Kentucky Research Foundation Stilbene analogs and methods of treating cancer
JP6155191B2 (ja) * 2011-10-02 2017-06-28 キユーピー株式会社 ＲＮＡ干渉によるｍＲＮＡ発現の抑制を促進する促進剤およびその用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090175803A1 (en) * 2008-01-08 2009-07-09 David Rubin Method and compositions for administering resveratrol and pterostilbene
US20110136751A1 (en) * 2009-10-06 2011-06-09 Green Molecular Use of Polyphenols in the Treatment of Cancer
WO2011051483A1 (en) * 2009-10-30 2011-05-05 Green Molecular, S.L Pterostilbene (pter) for use in the prevention and/or treatment of skin diseases, damages or injures

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Fatima Feddi, "Abstract 4239: Pterostilbene, a natural polyphenol, elicits full protection against ultraviolet B radiation-induced skin carcinogenesis", (20110415), URL: http://cancerres.aacrjournals.org/content/71/8_Supplement/4239.short *
RIMANDO A M, "Discovery of the cancer chemopreventive and hypocholesterolemic properties of pterostilbene", DATABASE BIOSIS, accession no. PREV200800402891 & In vitro cellular & developmental biology animal, Vol. 41, April 2005, p25A, USA *

Also Published As

Publication number Publication date
IN2014DN09990A (enExample) 2015-08-14
US10039725B2 (en) 2018-08-07
ZA201408893B (en) 2016-08-31
US8841350B2 (en) 2014-09-23
WO2013169291A2 (en) 2013-11-14
CN104768543A (zh) 2015-07-08
EP2846785A2 (en) 2015-03-18
EP2846785A4 (en) 2016-06-15
JP2015523963A (ja) 2015-08-20
US20120289605A1 (en) 2012-11-15
BR112014027646A2 (pt) 2017-06-27
AU2012379655A1 (en) 2014-11-20
US20150011650A1 (en) 2015-01-08
WO2013169291A3 (en) 2015-06-18
KR20150027081A (ko) 2015-03-11
MX2014013503A (es) 2015-11-13
CA2872623A1 (en) 2013-11-14

Similar Documents

Publication Publication Date Title
US10039725B2 (en) Method for treating non-melanoma skin cancer by inducing UDP-glucuronosyltransferase activity using pterostilbene
Gu et al. Isoliquiritigenin attenuates diabetic cardiomyopathy via inhibition of hyperglycemia-induced inflammatory response and oxidative stress
Li et al. Luteolin protects against diabetic cardiomyopathy by inhibiting NF-κB-mediated inflammation and activating the Nrf2-mediated antioxidant responses
Shang et al. Sulforaphane attenuation of experimental diabetic nephropathy involves GSK-3 beta/Fyn/Nrf2 signaling pathway
Mittal et al. Ameliorative potential of rutin in combination with nimesulide in STZ model of diabetic neuropathy: targeting Nrf2/HO-1/NF-kB and COX signalling pathway
Fang et al. Resveratrol alleviates diabetic cardiomyopathy in rats by improving mitochondrial function through PGC-1α deacetylation
Palliyaguru et al. Withaferin A induces Nrf2-dependent protection against liver injury: Role of Keap1-independent mechanisms
Marcheggiani et al. Modulation of Coenzyme Q10 content and oxidative status in human dermal fibroblasts using HMG-CoA reductase inhibitor over a broad range of concentrations. From mitohormesis to mitochondrial dysfunction and accelerated aging
Vella et al. PPAR-γ agonists as antineoplastic agents in cancers with dysregulated IGF axis
Sertznig et al. Peroxisome proliferator-activated receptors (PPARs) and the human skin: importance of PPARs in skin physiology and dermatologic diseases
Hsu et al. Resveratrol increases anti-aging Klotho gene expression via the activating transcription factor 3/c-Jun complex-mediated signaling pathway
US20140243267A1 (en) Use of nrf2 inducers to treat epidermolysis bullosa simplex and related diseases
Chun-Bin et al. The main active components of Curcuma zedoaria reduces collagen deposition in human lung fibroblast via autophagy
Wang et al. Geraniol improves endothelial function by inhibiting NOX-2 derived oxidative stress in high fat diet fed mice
Chen et al. Selenoprotein P is elevated in individuals with obesity, but is not independently associated with insulin resistance
Panieri et al. NRF2, a crucial modulator of skin cells protection against vitiligo, psoriasis, and cancer
Okubo et al. NAD (P) H dehydrogenase, quinone 1 (NQO 1), protects melanin‐producing cells from cytotoxicity of rhododendrol
Moon et al. Bay 11‐7082, an NF‐κB inhibitor, prevents post‐inflammatory hyperpigmentation through inhibition of inflammation and melanogenesis
Li et al. Effects of arsenic on wnt/β-catenin signaling pathway: A systematic review and meta-analysis
Schmidt et al. Regulation of heme oxygenase-1 expression by dopamine in cultured C6 glioma and primary astrocytes
Miao et al. Therapeutic effect of MG132 on the aortic oxidative damage and inflammatory response in OVE26 type 1 diabetic mice
Kwak et al. The cardioprotective effects of zileuton, a 5-lipoxygenase inhibitor, are mediated by COX-2 via activation of PKCδ
AU2015311799A1 (en) Topical pterostilbene compositions for use in treating UV-induced loss of barrier function in skin
Lương et al. The roles of vitamin D in seborrhoeic keratosis: possible genetic and cellular signalling mechanisms
Hosseinipoor et al. The effects of metformin monotherapy and combination of metformin and glibenclamide therapy on the expression of RAGE, Sirt1, and Nrf2 genes in peripheral blood mononuclear cells of type 2 diabetic patients: RAGE, Sirt1, and Nrf2 gene expression in PBMCof T2DM

Legal Events

Date Code Title Description
MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee